Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.40 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.40 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.40 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.40 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213460 | 0.99 | EPHX2 (0.44) | EPHX2GPR119TLR8USP2SMN1; SMN2 | |
| SCHEMBL2074818 | 0.90 | USP2 (0.44) | EPHX2GPR119TLR8USP2SMN1; SMN2 | |
| SCHEMBL25326751 | 0.88 | USP2 (0.40) | EPHX2GPR119TLR8USP2SMN1; SMN2 | |
| SCHEMBL24744872 | 0.85 | NR1H2 (0.38) | EPHX2GPR119HRH2HRH1 | |
| SCHEMBL5504226 | 0.82 | GPR119 (0.47) | GPR119 | |
| SCHEMBL20873847 | 0.82 | USP2 (0.53) | EPHX2TLR8USP2SMN1; SMN2ACKR3 | |
| SCHEMBL9743977 | 0.82 | HRH2 (0.54) | HRH2HRH1 | |
| SCHEMBL470992 | 0.81 | EPHX2 (0.47) | EPHX2TLR8USP2SMN1; SMN2ACKR3 | |
| SCHEMBL5572609 | 0.81 | USP2 (0.46) | EPHX2GPR119USP2SMN1; SMN2CHRM2 | |
| SCHEMBL16810242 | 0.81 | EPHX2 (0.47) | EPHX2TLR8USP2SMN1; SMN2ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3334735-B1 | PROCESSES FOR PREPARING AN FGFR INHIBITOR | PRINCIPIA BIOPHARMA INC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-12281110-B2 | Processes for preparing an FGFR inhibitor | PRINCIPIA BIOPHARMA, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240309000-A1 | Process for Preparing an FGFR Inhibitor | PRINCIPIA BIOPHARMA, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| EP-4351650-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NanoPharmaceuticals LLC (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117412772-A | Compositions and methods for dual targeted treatment of neuroendocrine tumors | 纳米药业有限责任公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-2022260918-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS LLC (US) | 2022-12-15 | — | — | WO | disclosed |
| US-11351137-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | NANOPHARMACEUTICALS LLC (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210299262-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS LLC | 2021-09-30 | — | — | US | disclosed |
| US-20210147417-A1 | PROCESSES FOR PREPARING AN FGFR INHIBITOR | PRINCIPIA BIOPHARMA INC. | 2021-05-20 | — | — | US | disclosed |
| US-10899760-B2 | Processes for preparing an FGFR inhibitor | PRINCIPIA BIOPHARMA, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200148680-A1 | PROCESSES FOR PREPARING AN FGFR INHIBITOR | PRINCIPIA BIOPHARMA INC. | 2020-05-14 | — | — | US | disclosed |
| US-20180215756-A1 | PROCESSES FOR PREPARING AN FGFR INHIBITOR | PRINCIPIA BIOPHARMA, INC. (US) | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240309000-A1 | Process for Preparing an FGFR Inhibitor | FGFR1, FGFR2, FGFR3 | CHRM2 4825/4885CHRM1 4805/4885CHRM4 4767/4885 |
| US-12281110-B2 | Processes for preparing an FGFR inhibitor | FGFR2, FGFR1, FGFR3 | CHRM2 4840/4885CHRM1 4823/4885CHRM4 4788/4885 |
| US-20180215756-A1 | PROCESSES FOR PREPARING AN FGFR INHIBITOR | FGFR2, FGFR1, FGFR3 | CHRM2 4840/4885CHRM1 4823/4885CHRM4 4788/4885 |
| US-20210147417-A1 | PROCESSES FOR PREPARING AN FGFR INHIBITOR | FGFR2, FGFR1, FGFR3 | CHRM2 4840/4885CHRM1 4823/4885CHRM4 4788/4885 |
| US-20200148680-A1 | PROCESSES FOR PREPARING AN FGFR INHIBITOR | FGFR2, FGFR1, FGFR3 | CHRM2 4840/4885CHRM1 4823/4885CHRM4 4788/4885 |
| US-10899760-B2 | Processes for preparing an FGFR inhibitor | FGFR2, FGFR1, FGFR3 | CHRM2 4840/4885CHRM1 4823/4885CHRM4 4788/4885 |
| US-11351137-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | THRB, TSHR, SLC6A2 | CHRM2 555/4885CHRM1 796/4885CHRM4 677/4885 |
| US-20210299262-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | THRB, TSHR, SLC6A2 | CHRM2 555/4885CHRM1 796/4885CHRM4 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.